Treace Medical Concepts Inc
$ 3.60
4.05%
01 Jun - close price
- Market Cap 224,460,000 USD
- Current Price $ 3.60
- High / Low $ 3.66 / 3.42
- Stock P/E N/A
- Book Value 1.19
- EPS -0.96
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -0.67 %
- 52 Week High 7.78
- 52 Week Low 1.17
About
Treace Medical Concepts, Inc., an orthopedic medical device company, is dedicated to the design, manufacture, and marketing of biological devices and / or solutions for foot and ankle surgeons in the United States. The company is headquartered in Ponte Vedra Beach, Florida.
Analyst Target Price
$4.00
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TMCI
2026-06-01 20:09:53
Treace Medical Concepts CEO John T. Treace purchased 50,000 shares of common stock in an open-market transaction on June 1, 2026, at a weighted average price of $3.5583 per share. This transaction increases his direct holdings to 7,323,833 shares, including restricted stock units. The filing also details indirect holdings through trusts and his spouse, though Treace disclaims beneficial ownership of these indirect shares.
2026-05-29 04:38:54
Treace Medical (NASDAQ:TMCI) CEO John Treace recently acquired 115,520 shares of the company's common stock for a total of $340,588 through open-market purchases between May 26 and May 28, 2026. These transactions increased his direct holdings to over 7.2 million shares, with additional indirect holdings. This comes as the stock has shown an 18% gain year-to-date, despite the company not being profitable in the last twelve months, and follows a Q1 2026 financial report that surpassed analyst expectations for EPS and revenue.
2026-05-28 20:09:10
John T. Trease, CEO of Treace Medical Concepts (TMCI), recently purchased 115,520 shares of common stock through open-market transactions on May 26, 27, and 28, 2026. These purchases, totaling approximately $340,589, increased his direct holdings to 7,273,833 shares, including restricted stock units. The CEO also holds indirect shares through trusts and his spouse, though he disclaims beneficial ownership of those.
2026-05-27 11:10:49
William Blair Investment Management LLC significantly reduced its stake in Treace Medical Concepts, Inc. (NASDAQ:TMCI) by 68.5% in the fourth quarter, selling 2,488,883 shares. Despite this, insider buying activity continued, with CEO John T. Treace acquiring additional shares. Treace Medical Concepts reported a smaller-than-expected loss and stronger revenue, though analysts largely maintain a "Reduce" rating for the stock.
2026-05-21 00:07:49
At its annual meeting, Treace Medical Concepts shareholders re-elected three Class II directors for three-year terms, signaling continued support for the company's current board and strategic direction. Investors also approved the executive compensation program and ratified Grant Thornton LLP as the independent auditor, ensuring continuity in financial oversight. An analyst rating on TMCI stock is a Hold with a $2.00 price target, while TipRanks’ AI Analyst, Spark, rates it Neutral due to weak financial performance despite strong gross margins.
2026-05-20 22:39:49
Treace Medical Concepts Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected Lance A. Berry, Elizabeth S. Hanna, and Jane E. Kiernan as Class II directors. They also approved the compensation for executive officers and ratified Grant Thornton LLP as the independent accounting firm for fiscal year 2026. The company recently reported better-than-expected Q1 2026 financial results, with shares gaining 11% in the past week and 15% year-to-date.
